Medivir AB (publ)
MVRBF · OTC
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.32 | 0.21 | 0.18 | -0.12 |
| FCF Yield | -5.76% | -4.65% | -3.43% | -8.47% |
| EV / EBITDA | -23.86 | -30.41 | -23.73 | -14.84 |
| Quality | ||||
| ROIC | -8.96% | -6.48% | -9.31% | -12.27% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -31.72% | 5.08% | 2.95% | 4.54% |
| Free Cash Flow Growth | -22.99% | -14.20% | 55.89% | -634.27% |
| Safety | ||||
| Net Debt / EBITDA | -0.49 | 0.50 | 0.21 | 0.15 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |